Presentation is loading. Please wait.

Presentation is loading. Please wait.

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum.

Similar presentations


Presentation on theme: "Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum."— Presentation transcript:

1 Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study  Alejandro Llanos-Cuentas, PhD, Martin Casapia, MPH, Raúl Chuquiyauri, PhD, Juan-Carlos Hinojosa, MD, Nicola Kerr, MA, Maria Rosario, PhD, Stephen Toovey, MD, Robert H Arch, PhD, Margaret A Phillips, PhD, Felix D Rozenberg, BA, Jade Bath, BA, Caroline L Ng, PhD, Annie N Cowell, MD, Elizabeth A Winzeler, PhD, David A Fidock, PhD, Mark Baker, PhD, Jörg J Möhrle, PhD, Rob Hooft van Huijsduijnen, PhD, Nathalie Gobeau, PhD, Nada Araeipour, MA, Nicole Andenmatten, PhD, Thomas Rückle, PhD, Stephan Duparc, MD  The Lancet Infectious Diseases  Volume 18, Issue 8, Pages (August 2018) DOI: /S (18) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2 Figure 1 Trial design and patients ITT=intention-to-treat.
The Lancet Infectious Diseases  , DOI: ( /S (18) ) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

3 Figure 2 Parasitaemia in the patients with Plasmodium falciparum malaria Parasitaemia was measured by microscopy. Patients received a single oral dose at 0 h with 400 mg (A) or 250 mg (B) DSM265. Patient F2003 developed suspected bacteraemia, a serious, non-treatment-related adverse event, and was discontinued from the study. The Lancet Infectious Diseases  , DOI: ( /S (18) ) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

4 Figure 3 Parasitaemia in the patients with Plasmodium vivax malaria
Parasitaemia was measured by microscopy. Patients received a single oral dose at 0 h with 400 mg (A), 600 mg (B), or 800 mg (C) DSM265. The Lancet Infectious Diseases  , DOI: ( /S (18) ) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions


Download ppt "Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum."

Similar presentations


Ads by Google